Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04920539 · ClinicalTrials.gov registry record · Phase 1
In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT04920539 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 56 participants.
The verdict
NCT04920539, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes.
Interventions
- DRUG Active Delta-9-THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04920539
The ClinicalTrials.gov registry entry for NCT04920539 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Active Delta-9-THC is the first listed.
NCT04920539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04920539 about?
NCT04920539 is a clinical study titled "In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans". In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes.
What is the current status of trial NCT04920539?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-02-08. Estimated completion is 2025-12-30.
What interventions are being tested in trial NCT04920539?
The interventions under investigation include: Active Delta-9-THC (DRUG).
Who is sponsoring clinical trial NCT04920539?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.